Research Projects & Grants

Federal

  • SWOG - PACCT-1: Program of the assessment of clinical tests (PACCT-1): Trial assigning individualized options for treatment: the TAILORx trial, Role: Investigator, Eastern Cooperative Oncology Group, (11/2024 - 11/2025) Status: Approved

For Profit Organization

  • SWOG-A081105: randomized study of Erlotinib VS Observation in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-small Cell Lung Cancer (NSCLC), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • Amgen Inc., 20190135: A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (plNN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H), Role: Investigator, Amgen, Inc., (06/2024 - 06/2025) Status: Approved
  • J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Investigator, Eli Lilly & Co., (06/2024 - 06/2025) Status: Approved
  • A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (02/2024 - 02/2025) Status: Approved
  • Merck Sharp & Dohme LLC. MK-7339-013: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment- Naïve limited-Stage Small Cell Lung Cancer (LS-SCLC), Role: Investigator, Merck, Sharp & Dohme Corp., (02/2024 - 02/2025) Status: Approved
  • A Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03), Role: Investigator, AstraZeneca Pharmaceuticals, L.P. (USA), (01/2024 - 01/2025) Status: Approved
  • SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers, Role: Investigator, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
  • SWOG E4512: a phase III double-blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus Placebo for patients with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein, Role: Investigator, Southwest Oncology Group, (11/2023 - 11/2024) Status: Approved
  • SWOG A151216: adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST), Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors, Role: Investigator, Apollomics Inc., (09/2024 - 09/2025) Status: Approved
  • SWOG S1507: A phase II trial of Trametinib with Docetaxel in patients with KRAS mutation positive non-small cell lung cancer (NSCLC) and progressive disease following one or two prior systematic therapies, Role: Investigator, Southwest Oncology Group, (05/2023 - 05/2024) Status: Completed
  • LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Preciously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)” S1900F, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)”, Role: Investigator, Southwest Oncology Group, Status: Completed

Internal

  • Investigator Initiated: A phase II trial of preoperative chemotherapy (with gemcitabine and nab-paclitaxel) and stereotactic body radiotherapy followed by surgery and chemotherapy in patients with resectable pancreatic adenocarcinoma, Role: Investigator, LLU Dept. of Surgery, (09/2024 - 09/2025) Status: Approved
  • Registry for patients who have received endocrine therapy for breast cancer to assess relationship between endocrine therapy and non-alcoholic liver disease, Role: Investigator, LLU Dept. of Medicine, (10/2024) Status: Approved